{"transactions":[{"id":2079143,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":121387,"kind":"person","name":"Jones Michael L","position":1,"cik":"0001800060","reported_name":"Jones Michael L","relationship":{"officer":true,"officer_title":"Exec. Director, Finance - PAO"}}],"security":"Emp. Stock Option (Right to Buy)","published_at":"2022-12-21T21:36:30.000Z","date":"2022-12-19","kind":"grant","acquired":true,"shares":8500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant."}],"balance_after":8500,"derivative":{"exercise_price":10.63,"exercise_date":"2023-12-19","expiration_date":"2032-12-19","underlying":"Common Stock","underlying_shares":8500},"source":{"system":"sec-edgar","filing":"0001127602-22-028078","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760222028078/form4.xml","form_type":"4"}},{"id":2079142,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":121387,"kind":"person","name":"Jones Michael L","position":1,"cik":"0001800060","reported_name":"Jones Michael L","relationship":{"officer":true,"officer_title":"Exec. Director, Finance - PAO"}}],"security":"Common Stock","published_at":"2022-12-21T21:36:30.000Z","date":"2022-12-19","kind":"grant","acquired":true,"shares":5900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Annual award of Restricted Stock Units which will vest 25% on each of the first, second, third and fourth anniversaries of the date of grant."}],"balance_after":16653,"source":{"system":"sec-edgar","filing":"0001127602-22-028078","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760222028078/form4.xml","form_type":"4"}},{"id":2082610,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":121387,"kind":"person","name":"Jones Michael L","position":1,"cik":"0001800060","reported_name":"Jones Michael L","relationship":{"officer":true,"officer_title":"Exec. Director, Finance - PAO"}}],"security":"Common Stock","published_at":"2022-12-19T21:45:25.000Z","date":"2022-12-15","kind":"sale","acquired":false,"shares":445,"price":10.9,"value":4850.5,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2022 to cover tax withholding obligations in connection with the vesting of 1,462 Restricted Stock Units. The sale occurred automatically to satisfy tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary transaction by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $10.54 to $11.40. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":10753,"source":{"system":"sec-edgar","filing":"0001127602-22-027870","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760222027870/form4.xml","form_type":"4"}},{"id":2099105,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":121387,"kind":"person","name":"Jones Michael L","position":1,"cik":"0001800060","reported_name":"Jones Michael L","relationship":{"officer":true,"officer_title":"Exec. Director, Finance - PAO"}}],"security":"Emp. Stock Option (Right to Buy)","published_at":"2022-12-02T23:36:04.000Z","date":"2022-12-01","kind":"exercise","acquired":false,"shares":8600,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":1.42,"exercise_date":"2014-01-01","expiration_date":"2023-01-01","underlying":"Common Stock","underlying_shares":8600},"source":{"system":"sec-edgar","filing":"0001127602-22-026834","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760222026834/form4.xml","form_type":"4"}},{"id":2099104,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":121387,"kind":"person","name":"Jones Michael L","position":1,"cik":"0001800060","reported_name":"Jones Michael L","relationship":{"officer":true,"officer_title":"Exec. Director, Finance - PAO"}}],"security":"Common Stock","published_at":"2022-12-02T23:36:04.000Z","date":"2022-12-01","kind":"sale","acquired":false,"shares":8600,"price":13.01,"value":111886.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $13.01 to $13.03. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":11198,"source":{"system":"sec-edgar","filing":"0001127602-22-026834","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760222026834/form4.xml","form_type":"4"}},{"id":2099103,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":121387,"kind":"person","name":"Jones Michael L","position":1,"cik":"0001800060","reported_name":"Jones Michael L","relationship":{"officer":true,"officer_title":"Exec. Director, Finance - PAO"}}],"security":"Common Stock","published_at":"2022-12-02T23:36:04.000Z","date":"2022-12-01","kind":"exercise","acquired":true,"shares":8600,"price":1.42,"value":12212.0,"ownership":{"direct":true},"balance_after":19798,"source":{"system":"sec-edgar","filing":"0001127602-22-026834","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760222026834/form4.xml","form_type":"4"}},{"id":2357061,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":121387,"kind":"person","name":"Jones Michael L","position":1,"cik":"0001800060","reported_name":"Jones Michael L","relationship":{"officer":true,"officer_title":"Exec. Director, Finance - PAO"}}],"security":"Emp. Stock Option (Right to Buy)","published_at":"2022-03-03T22:04:41.000Z","date":"2022-03-01","kind":"exercise","acquired":false,"shares":2300,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":4.73,"exercise_date":"2013-03-01","expiration_date":"2022-03-01","underlying":"Common Stock","underlying_shares":2300},"source":{"system":"sec-edgar","filing":"0001127602-22-008047","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760222008047/form4.xml","form_type":"4"}},{"id":2357060,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":121387,"kind":"person","name":"Jones Michael L","position":1,"cik":"0001800060","reported_name":"Jones Michael L","relationship":{"officer":true,"officer_title":"Exec. Director, Finance - PAO"}}],"security":"Common Stock","published_at":"2022-03-03T22:04:41.000Z","date":"2022-03-01","kind":"sale","acquired":false,"shares":2300,"price":17.2,"value":39560.0,"ownership":{"direct":true},"balance_after":11198,"source":{"system":"sec-edgar","filing":"0001127602-22-008047","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760222008047/form4.xml","form_type":"4"}},{"id":2357059,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":121387,"kind":"person","name":"Jones Michael L","position":1,"cik":"0001800060","reported_name":"Jones Michael L","relationship":{"officer":true,"officer_title":"Exec. Director, Finance - PAO"}}],"security":"Common Stock","published_at":"2022-03-03T22:04:41.000Z","date":"2022-03-01","kind":"exercise","acquired":true,"shares":2300,"price":4.73,"value":10879.0,"ownership":{"direct":true},"balance_after":13498,"source":{"system":"sec-edgar","filing":"0001127602-22-008047","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760222008047/form4.xml","form_type":"4"}},{"id":2470727,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":121387,"kind":"person","name":"Jones Michael L","position":1,"cik":"0001800060","reported_name":"Jones Michael L","relationship":{"officer":true,"officer_title":"Exec. Director, Finance - PAO"}}],"security":"Emp. Stock Option (Right to Buy)","published_at":"2021-12-16T22:16:28.000Z","date":"2021-12-14","kind":"grant","acquired":true,"shares":11700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant."}],"balance_after":11700,"derivative":{"exercise_price":11.43,"exercise_date":"2022-12-14","expiration_date":"2031-12-14","underlying":"Common Stock","underlying_shares":11700},"source":{"system":"sec-edgar","filing":"0001127602-21-031141","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760221031141/form4.xml","form_type":"4"}},{"id":2470726,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":121387,"kind":"person","name":"Jones Michael L","position":1,"cik":"0001800060","reported_name":"Jones Michael L","relationship":{"officer":true,"officer_title":"Exec. Director, Finance - PAO"}}],"security":"Common Stock","published_at":"2021-12-16T22:16:28.000Z","date":"2021-12-14","kind":"grant","acquired":true,"shares":5850,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Annual award of Restricted Stock Units which will vest 25% on each of the first, second, third and fourth anniversaries of the date of grant."}],"balance_after":11198,"source":{"system":"sec-edgar","filing":"0001127602-21-031141","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760221031141/form4.xml","form_type":"4"}},{"id":2776796,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":121387,"kind":"person","name":"Jones Michael L","position":1,"cik":"0001800060","reported_name":"Jones Michael L","relationship":{"officer":true,"officer_title":"Exec. Director, Finance - PAO"}}],"security":"Emp. Stock Option (Right to Buy)","published_at":"2021-03-22T20:19:34.000Z","date":"2021-03-18","kind":"exercise","acquired":false,"shares":4500,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":3.51,"exercise_date":"2012-03-21","expiration_date":"2021-03-21","underlying":"Common Stock","underlying_shares":4500},"source":{"system":"sec-edgar","filing":"0001127602-21-011668","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760221011668/form4.xml","form_type":"4"}},{"id":2776795,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":121387,"kind":"person","name":"Jones Michael L","position":1,"cik":"0001800060","reported_name":"Jones Michael L","relationship":{"officer":true,"officer_title":"Exec. Director, Finance - PAO"}}],"security":"Common Stock","published_at":"2021-03-22T20:19:34.000Z","date":"2021-03-18","kind":"exercise","acquired":true,"shares":4500,"price":3.51,"value":15795.0,"ownership":{"direct":true},"balance_after":5348,"source":{"system":"sec-edgar","filing":"0001127602-21-011668","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760221011668/form4.xml","form_type":"4"}},{"id":2941059,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":121387,"kind":"person","name":"Jones Michael L","position":1,"cik":"0001800060","reported_name":"Jones Michael L","relationship":{"officer":true,"officer_title":"Exec. Director, Finance - PAO"}}],"security":"Emp. Stock Option (Right to Buy)","published_at":"2020-12-17T21:41:00.000Z","date":"2020-12-15","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant."}],"balance_after":30000,"derivative":{"exercise_price":8.31,"exercise_date":"2021-12-15","expiration_date":"2030-12-15","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001127602-20-031800","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760220031800/form4.xml","form_type":"4"}},{"id":2955700,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":121387,"kind":"person","name":"Jones Michael L","position":1,"cik":"0001800060","reported_name":"Jones Michael L","relationship":{"officer":true,"officer_title":"Exec. Director, Finance - PAO"}}],"security":"Emp. Stock Option (Right to Buy)","published_at":"2020-12-07T21:24:43.000Z","date":"2020-12-03","kind":"grant","acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On December 3, 2020, the U.S. Food and Drug Administration approved oral, once-daily ORLADEYO? (berotralstat) for prophylaxis to prevent attacks of hereditary angioedema in adults and pediatric patients 12 years and older. As a result, one of the vesting criteria associated with the performance-based stock options awarded to the reporting person on August 8, 2013 has been met. Therefore, 25% of such performance-based stock options vested on December 3, 2020."}],"balance_after":5000,"derivative":{"exercise_price":5.45,"exercise_date":"2020-12-03","expiration_date":"2023-08-08","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001127602-20-030706","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760220030706/form4.xml","form_type":"4"}},{"id":3250625,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":121387,"kind":"person","name":"Jones Michael L","position":1,"cik":"0001800060","reported_name":"Jones Michael L","relationship":{"officer":true,"officer_title":"Exec. Director, Finance - PAO"}}],"security":"Emp. Stock Option (Right to Buy)","published_at":"2020-02-25T21:49:16.000Z","date":"2020-02-21","kind":"grant","acquired":true,"shares":2800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On February 21, 2020, the company received payment for 20,000 doses of RAPIVAB? (peramivir injection) delivered to the U.S. Department of Health and Human Services under the company's procurement contract. As a result, one of the vesting criteria associated with the performance-based stock options awarded to all employees in December 2014, excluding the Chief Executive Officer, has been met. Therefore, 20% of the performance-based stock options vested."}],"balance_after":2800,"derivative":{"exercise_price":11.13,"exercise_date":"2020-02-21","expiration_date":"2024-12-22","underlying":"Common Stock","underlying_shares":2800},"source":{"system":"sec-edgar","filing":"0001127602-20-007687","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760220007687/form4.xml","form_type":"4"}},{"id":3264775,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":121387,"kind":"person","name":"Jones Michael L","position":1,"cik":"0001800060","reported_name":"Jones Michael L","relationship":{"officer":true,"officer_title":"Exec. Director, Finance - PAO"}}],"security":"Emp. Stock Option (Right to Buy)","published_at":"2020-02-19T22:13:18.000Z","date":"2020-02-14","kind":"grant","acquired":true,"shares":4900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On February 18, 2019, BioCryst Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has accepted and filed its new drug application for the approval of oral, once daily berotralstat (BCX7353) for the prevention of hereditary angioedema attacks. As a result, one of the vesting criteria associated with the performance-based stock options awarded to all employees in December 2014, excluding the Chief Executive Officer, has been met. Therefore, 35% of the performance-based stock options vested."}],"balance_after":4900,"derivative":{"exercise_price":11.13,"exercise_date":"2020-02-14","expiration_date":"2024-12-22","underlying":"Common Stock","underlying_shares":4900},"source":{"system":"sec-edgar","filing":"0001127602-20-006508","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760220006508/form4.xml","form_type":"4"}}]}